Based on the key indicators related to Enanta Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Enanta Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March. At present, Enanta Pharmaceuticals' Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 69.5 M, whereas Common Stock Shares Outstanding is forecasted to decline to about 18.4 M. Key indicators impacting Enanta Pharmaceuticals' financial strength include:
Investors should never underestimate Enanta Pharmaceuticals' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Enanta Pharmaceuticals' cash flow, debt, and profitability to make informed and accurate decisions about investing in Enanta Pharmaceuticals.
Net Income
(99.22 Million)
Enanta
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Net Income Per Share
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Price Fair Value
Return On Equity
Change To Inventory
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Other Cashflows From Investing Activities
Change To Liabilities
Sale Purchase Of Stock
Investments
Change Receivables
Total Cashflows From Investing Activities
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Change To Netincome
Net Borrowings
Change To Operating Activities
Common Stock Shares Outstanding
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Cash And Short Term Investments
Net Receivables
Common Stock Total Equity
Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Preferred Stock Total Equity
Total Current Assets
Accumulated Other Comprehensive Income
Common Stock
Property Plant Equipment
Current Deferred Revenue
Long Term Debt
Retained Earnings Total Equity
Short Long Term Debt Total
Net Tangible Assets
Capital Surpluse
Long Term Investments
Short Long Term Debt
Non Current Liabilities Other
Deferred Long Term Asset Charges
Short Term Debt
Long Term Debt Total
Capital Lease Obligations
Net Invested Capital
Net Working Capital
Capital Stock
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Cost Of Revenue
Net Income Applicable To Common Shares
Net Income From Continuing Ops
Non Operating Income Net Other
Tax Provision
Interest Income
Net Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Enanta Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Enanta Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Enanta Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the presentation of Enanta Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Enanta Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Enanta Pharmaceuticals' management manipulating its earnings.
Enanta Pharmaceuticals Stock Summary
Enanta Pharmaceuticals competes with Monte Rosa, Design Therapeutics, Werewolf Therapeutics, Ikena Oncology, and Stoke Therapeutics. Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts. Enanta Pharmaceutica operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 155 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Enanta Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Enanta Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Enanta Pharmaceuticals competition to find correlations between indicators driving Enanta Pharmaceuticals's intrinsic value. More Info.
Enanta Pharmaceuticals is rated below average in return on equity category among its peers. It is rated # 2 in return on asset category among its peers . At present, Enanta Pharmaceuticals' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Enanta Pharmaceuticals' earnings, one of the primary drivers of an investment's value.
Enanta Pharmaceuticals Systematic Risk
Enanta Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Enanta Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Enanta Pharmaceuticals correlated with the market. If Beta is less than 0 Enanta Pharmaceuticals generally moves in the opposite direction as compared to the market. If Enanta Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Enanta Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Enanta Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Enanta Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Enanta Pharmaceuticals Thematic Clasifications
Enanta Pharmaceuticals is part of Trump Equities investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Companies that have responded positively to Trump presidency. Stocks that have significantly increased in valuation since Trump was elected president of the United States
This theme covers Companies that have responded positively to Trump presidency. Stocks that have significantly increased in valuation since Trump was elected president of the United States. Get More Thematic Ideas
Today, most investors in Enanta Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Enanta Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Enanta Pharmaceuticals growth as a starting point in their analysis.
Price Earnings To Growth Ratio
0.12
At present, Enanta Pharmaceuticals' Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.
Enanta Pharmaceuticals February 26, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Enanta Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Enanta Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Enanta Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Enanta Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Enanta Pharmaceuticals's daily price indicators and compare them against related drivers.
When running Enanta Pharmaceuticals' price analysis, check to measure Enanta Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enanta Pharmaceuticals is operating at the current time. Most of Enanta Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Enanta Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enanta Pharmaceuticals' price. Additionally, you may evaluate how the addition of Enanta Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.